Polio consultant awarded prestigious Gates Vaccine Innovation Award

The Bill and Melinda Gates Foundation has awarded its prestigious Vaccine Innovation Award to polio consultant Dr Asm Amjad Hossain

Melinda Gates, co-chair of the Bill and Melinda Gates Foundation, meets with Dr Asm Amjad Hossain, the recipient of the first Gates Vaccine Innovation Award Bill and Melinda Gates Foundation

Dr Hossain, originally from Bangladesh and currently based in Nigeria supporting the country’s polio eradication efforts there, received the Award from among 117 nominations encompassing a range of innovative solutions to increase vaccination coverage.

The Award is in direct recognition of Dr Hossain’s innovative work in raising immunization coverage rates in key districts of Bangladesh, by institutionalising processees for registering pregnant women with expected delivery dates, annual schedules for vaccine sessions, and key active community outreach strategies. “(These innovations) show how looking at old problems in new ways can make a profound difference,” said Mr Bill Gates, co-chair of the Bill and Melinda Gates Foundation. “Improvements like these are spreading to other locations because of the commitment and creativity of Dr Hossain and many others like him.”

The Award was established by the Bill and Melinda Gates Foundation to recognize and celebrate revolutionary ways in which children in the poorest parts of the world are immunized. The Award winner is recognized with US$250,000 and personally acknowledged by Gates Foundation leadership.

Related


Related News

   19/10/2021
For a few incredible eradicators, a life’s purpose doesn’t stop at retirement
   19/10/2021
Update on polio eradication efforts in Pakistan for September 2021
   18/10/2021
WHO and UNICEF welcome the decision by the Taliban leadership supporting the resumption of house-to-house polio vaccination across Afghanistan.
   13/10/2021
Virus isolated from Rivne province in north-west of country
   10/10/2021
The recommendation further advances nOPV2 as a critical new tool in the fight against circulating vaccine-derived poliovirus type 2 (cVDPV2)
   29/09/2021
More often than not, the road to a meaningful triumph is a bumpy one.